Dr D wins with his wit yet again, answers chef who called Indian food 'terrible'
The chef's comments were named a tasteless generalisation.
Avoid metals in long term, go for India focused pharma cos: Sudip Bandyopadhyay
The uncertainties on the back of the tariff war have not ende...
Diagnostic cos fall on Reliance Life’s proposed entry
On Monday, these three stocks fell between 1 per cent and 3 per cent.
Chinese strategy: Dr Reddy's outsources part manufacturing to local parties
The company which won the tender to market Olanzapine drug in China, is expected to launch it beginning next year, the official said. The products are manufactured either in the plant owned by KRRP in China, or partners in China, or in India by Dr. Reddy's, the official further said.
Analyst Calls: Bandhan Bank, NHPC, Gail, Dr Reddy's Lab
JM Financial has maintained its buy rating on Bandhan Bank with a target price of Rs 710.
SBI Cap Securities upgrades Dr Reddy's Labs to buy, target price Rs 3,200
Buy Dr. Reddy's Laboratories Ltd. at a price target of Rs 3200.0 .
Dr Reddy's forays into nutrition segment; launches diabetic-friendly drink
It is a first-of-its-kind under Dr Reddy's nutrition portfolio and clinically proven to help manage blood glucose levels among Indian patients. The brand 'Celevida' is derived from two words 'Celebration' and 'Vida', which means 'Celebrate Life'. It is available in two flavours Kesar Elachi and Chocolate, which are taste tested with over 300 diabetics and prediabetics, it said.
Share market update: Nifty Pharma index dips; Dr. Reddy's Lab down 2%
The Nifty Pharma index was trading 0.37 per cent down at 8243.
Dr D's column: Will Israeli techies be able to decipher details about Indians?
as hackers prying open your WhatsApp secrets, Israeli techies are the elite of the elite.
Share market update: Pharma shares up; Cipla gains 1%
The Nifty Pharma index was trading 0.14 per cent up at 8055.95.
Buy Dr. Reddy's Laboratories, price target Rs 3,060: Sagar Doshi
The analyst suggested a stoploss at Rs 2920.
Ask Dr. D: Prince Andrew wants to know how he can escape the Jeffrey Epstein scandal
Dr. D gives Prince Andrew a much-needed reality check.
CLSA retains buy on Dr Lal Pathlabs, raises target price to Rs 1,800
Buy Dr. Lal Pathlabs Ltd. at a price target of Rs 1800.0 .
Share market update: Nifty Pharma index dips; Glenmark Pharma down 2%
The Nifty Pharma index was trading 0.71 per cent down at 8131.70.
Analyst Calls: Dr Reddy's Lab, Sudarshan Chemicals, Varun Beverages, BEL
Ambit Capital has maintained buy rating on Sudarshan Chemicals with a target price of Rs 420.
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service